![logo](/logos/NOX.AX.webp)
Noxopharm Limited
ASX:NOX.AX
0.07 (AUD) • At close July 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Noxopharm Limited |
Symbool | NOX.AX |
Munteenheid | AUD |
Prijs | 0.072 |
Beurswaarde | 21,041,136 |
Dividendpercentage | 0% |
52-weken bereik | 0.033 - 0.165 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gisela Mautner |
Website | https://www.noxopharm.com |
An error occurred while fetching data.
Over Noxopharm Limited
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)